{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:29:36Z","timestamp":1793507376309,"version":"4.5.0"},"reference-count":66,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"\n Importance<\/jats:title>\n There lacks data clarifying the meningioma risk conferred by depot medroxyprogesterone acetate in the US.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine the relative risk of meningioma diagnosis in women using depot medroxyprogesterone acetate and other related progestins.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective population-based cohort study used data from TriNetX, a US national database of 68 health care organizations. Data were analyzed from December 2004 to December 2024. The incidence of meningioma diagnosis was compared between treatment groups through propensity-score matched analyses. Participants included a sample of females with use of only 1 of the following progestins\/contraceptives: depot medroxyprogesterone acetate, oral medroxyprogesterone acetate, combined oral contraceptives, intrauterine devices, progestin only pills, or subdermal implantable contraceptive. The control group included females without use of these hormonal treatments. Of the 118\u202f289\u202f082 total patients in TriNetX at the time of analysis, 61\u202f588\u202f239 patients were female and eligible.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n \n Patients were defined using diagnostic codes from the\n International Classification of Diseases, Current Procedural Terminology<\/jats:italic>\n , and RxNorm codes within TriNetX.\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measure<\/jats:title>\n The main outcome was meningioma diagnosis. Relative risks and number needed to harm were calculated.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n There were 10\u202f425\u202f438 patients that met inclusion criteria with a mean age of 33.4 years at inclusion. After propensity score matching, 88\u202f667 patients with mean age of 26.2 years at inclusion were in the depot medroxyprogesterone acetate group. Use of depot medroxyprogesterone acetate had a relative risk of 2.43 (95% CI, 1.77-3.33) for meningioma diagnosis compared with controls. Notably, this risk was confined for patients with longer than 4 years of exposure or starting the prescription at ages older than 31 years. Oral medroxyprogesterone acetate had increased relative risk of 1.18 (95% CI, 1.10-1.27) compared with controls. No increased risk of meningioma diagnosis was found with any other contraceptive. The number needed to harm for the depot medroxyprogesterone acetate was 1152 patients and 3020 patients for oral medroxyprogesterone acetate.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this study, women receiving depot medroxyprogesterone acetate had a greater relative risk of subsequent meningioma diagnosis, especially with prolonged exposures and starting the medication at older ages. The high number needed to harm suggests low clinical risk overall.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaneurol.2025.3011","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T15:00:34Z","timestamp":1756825234000},"page":"1094","source":"Crossref","is-referenced-by-count":24,"title":["Depot Medroxyprogesterone Acetate and Risk of Meningioma in the US"],"prefix":"10.1001","volume":"82","author":[{"given":"Tianqi","family":"Xiao","sequence":"first","affiliation":[{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio"},{"name":"Rosa Ella Burkhardt Brain Tumor & Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav","family":"Kumar","sequence":"additional","affiliation":[{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio"},{"name":"Rosa Ella Burkhardt Brain Tumor & Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Lobbous","sequence":"additional","affiliation":[{"name":"Rosa Ella Burkhardt Brain Tumor & Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, Ohio"},{"name":"Department of Neurology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Yogi-Morren","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranay","family":"Soni","sequence":"additional","affiliation":[{"name":"Rosa Ella Burkhardt Brain Tumor & Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, Ohio"},{"name":"Department of Neurological Surgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo F.","family":"Recinos","sequence":"additional","affiliation":[{"name":"Rosa Ella Burkhardt Brain Tumor & Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, Ohio"},{"name":"Department of Neurological Surgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun R.","family":"Kshettry","sequence":"additional","affiliation":[{"name":"Rosa Ella Burkhardt Brain Tumor & Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, Ohio"},{"name":"Department of Neurological Surgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"noi250057r1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11060-010-0386-3","article-title":"Epidemiology and etiology of meningioma.","volume":"99","author":"Wiemels","year":"2010","journal-title":"J Neurooncol"},{"issue":"S6","key":"noi250057r2","doi-asserted-by":"publisher","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","article-title":"CBTRUS Statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2017-2021.","volume":"26","author":"Price","year":"2024","journal-title":"Neuro Oncol"},{"key":"noi250057r3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1157182","article-title":"Epidemiology and survival of non-malignant and malignant meningiomas in middle-aged females, 2004-2018.","volume":"13","author":"Cao","year":"2023","journal-title":"Front Oncol"},{"key":"noi250057r4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bas.2024.104154","article-title":"Recommendations on the management of meningioma and sex hormone therapy: the results of a collaborative effort between neurosurgical, endocrine and gynecological societies.","volume":"5","author":"Reuter","year":"2024","journal-title":"Brain Spine"},{"issue":"10","key":"noi250057r5","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s00701-015-2532-3","article-title":"Growth stabilization and regression of meningiomas after discontinuation of cyproterone acetate: a case series of 12 patients.","volume":"157","author":"Bernat","year":"2015","journal-title":"Acta Neurochir (Wien)"},{"issue":"1","key":"noi250057r6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11060-020-03576-8","article-title":"Female gender and exogenous progesterone exposition as risk factors for spheno-orbital meningiomas.","volume":"149","author":"Apra","year":"2020","journal-title":"J Neurooncol"},{"key":"noi250057r7","doi-asserted-by":"publisher","first-page":"e1261","DOI":"10.1016\/j.wneu.2018.03.187","article-title":"Houdini tumor: case report and literature review of pregnancy-associated meningioma.","volume":"114","author":"Chakravarthy","year":"2018","journal-title":"World Neurosurg"},{"issue":"3","key":"noi250057r8","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3171\/2012.9.JNS12811","article-title":"Exogenous hormone use, reproductive factors, and risk of intracranial meningioma in females.","volume":"118","author":"Claus","year":"2013","journal-title":"J Neurosurg"},{"issue":"2","key":"noi250057r9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1136\/jnnp.21.2.89","article-title":"The relapsing course of certain meningiomas in relation to pregnancy and menstruation.","volume":"21","author":"Bickerstaff","year":"1958","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"noi250057r10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004321","article-title":"Menopausal hormone therapy and central nervous system tumors: Danish nested case-control study.","volume":"20","author":"Pourhadi","year":"2023","journal-title":"PLoS Med"},{"key":"noi250057r11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4103\/sni.sni_22_18","article-title":"Multiple meningiomas in two male-to-female transsexual patients with hormone replacement therapy: a report of two cases and a brief literature review.","volume":"9","author":"Raj","year":"2018","journal-title":"Surg Neurol Int"},{"issue":"3","key":"noi250057r12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1227\/01.NEU.0000350876.91495.E0","article-title":"The association of breast cancer and meningioma in men and women.","volume":"65","author":"Rao","year":"2009","journal-title":"Neurosurgery"},{"issue":"1","key":"noi250057r13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10143-016-0762-3","article-title":"Unique features of pregnancy-related meningiomas: lessons learned from 148 reported cases and theoretical implications of a prolactin modulated pathogenesis.","volume":"41","author":"Laviv","year":"2018","journal-title":"Neurosurg Rev"},{"key":"noi250057r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.crwh.2023.e00541","article-title":"Meningioma in the third trimester of pregnancy: a case report.","volume":"39","author":"Ettore","year":"2023","journal-title":"Case Rep Womens Health"},{"issue":"23","key":"noi250057r15","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1056\/NEJMc071938","article-title":"Growth of a meningioma in a transsexual patient after estrogen-progestin therapy.","volume":"357","author":"Gazzeri","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"noi250057r16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.18620","article-title":"The association between meningioma and breast cancer: a systematic review and meta-analysis.","volume":"6","author":"Degeneffe","year":"2023","journal-title":"JAMA Netw Open"},{"key":"noi250057r17","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-16-0054","article-title":"Growth of a progesterone receptor-positive meningioma in a female patient with congenital adrenal hyperplasia.","author":"O\u2019Shea","year":"2016","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"3","key":"noi250057r18","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3390\/cancers15030980","article-title":"Hormone receptor expression in meningiomas: a systematic review.","volume":"15","author":"Agopiantz","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"noi250057r19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/00006123-199308000-00005","article-title":"Immunohistochemical detection of female sex hormone receptors in meningiomas: correlation with clinical and histological features.","volume":"33","author":"Brandis","year":"1993","journal-title":"Neurosurgery"},{"key":"noi250057r20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.611218","article-title":"Progesterone receptor expression in meningiomas: pathological and prognostic implications.","volume":"11","author":"Maiuri","year":"2021","journal-title":"Front Oncol"},{"issue":"12","key":"noi250057r21","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/S0959-8049(01)00146-0","article-title":"Progesterone receptor isoform expression in human meningiomas.","volume":"37","author":"Verheijen","year":"2001","journal-title":"Eur J Cancer"},{"issue":"1","key":"noi250057r22","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1158\/0008-5472.CAN-07-1796","article-title":"Specific genes expressed in association with progesterone receptors in meningioma.","volume":"68","author":"Claus","year":"2008","journal-title":"Cancer Res"},{"issue":"18","key":"noi250057r23","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1001\/jama.2024.5923","article-title":"Use of progestogen tied to higher chance of benign brain tumor.","volume":"331","author":"Harris","year":"2024","journal-title":"JAMA"},{"key":"noi250057r24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078078","article-title":"Use of progestogens and the risk of intracranial meningioma: national case-control study.","volume":"384","author":"Roland","year":"2024","journal-title":"BMJ"},{"issue":"20","key":"noi250057r25","doi-asserted-by":"publisher","first-page":"739","DOI":"10.15585\/mmwr.mm7020a2","article-title":"Update to US selected practice recommendations for contraceptive use: self-administration of subcutaneous depot medroxyprogesterone acetate.","volume":"70","author":"Curtis","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"noi250057r26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0010-7824(03)00136-7","article-title":"Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety.","volume":"68","author":"Westhoff","year":"2003","journal-title":"Contraception"},{"issue":"19","key":"noi250057r27","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.3390\/cancers16193362","article-title":"The association between medroxyprogesterone acetate exposure and meningioma.","volume":"16","author":"Griffin","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"3","key":"noi250057r28","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies.","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"9","key":"noi250057r29","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1111\/ene.15423","article-title":"Risk of intracranial meningioma with three potent progestogens: a population-based case-control study.","volume":"29","author":"Hoisnard","year":"2022","journal-title":"Eur J Neurol"},{"issue":"6","key":"noi250057r30","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/j.1365-2125.2011.04031.x","article-title":"Risk of meningioma among users of high doses of cyproterone acetate as compared with the general population: evidence from a population-based cohort study.","volume":"72","author":"Gil","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"37","key":"noi250057r31","doi-asserted-by":"publisher","first-page":"n37","DOI":"10.1136\/bmj.n37","article-title":"Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study.","volume":"372","author":"Weill","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"noi250057r32","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1038\/s41598-022-05773-z","article-title":"A systematic review and meta-analysis of the association between cyproterone acetate and intracranial meningiomas.","volume":"12","author":"Lee","year":"2022","journal-title":"Sci Rep"},{"issue":"12","key":"noi250057r33","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1007\/s10552-010-9634-2","article-title":"Exogenous sex hormone use and risk of meningioma: a population-based case-control study in Finland.","volume":"21","author":"Korhonen","year":"2010","journal-title":"Cancer Causes Control"},{"issue":"1","key":"noi250057r34","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1471-2407-6-152","article-title":"Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study.","volume":"6","author":"Custer","year":"2006","journal-title":"BMC Cancer"},{"issue":"15","key":"noi250057r35","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1016\/j.ejca.2013.05.026","article-title":"Hormone replacement therapy increases the risk of cranial meningioma.","volume":"49","author":"Andersen","year":"2013","journal-title":"Eur J Cancer"},{"issue":"5","key":"noi250057r36","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3171\/2009.8.JNS09201","article-title":"Regression of multiple intracranial meningiomas after cessation of long-term progesterone agonist therapy.","volume":"112","author":"Vadivelu","year":"2010","journal-title":"J Neurosurg"},{"issue":"4","key":"noi250057r37","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00701-019-03848-x","article-title":"Spontaneous regression of meningiomas after interruption of nomegestrol acetate: a series of three patients.","volume":"161","author":"Passeri","year":"2019","journal-title":"Acta Neurochir (Wien)"},{"issue":"3","key":"noi250057r38","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.31557\/APJCP.2022.23.3.1047","article-title":"Association of hormonal contraception with meningioma location in Indonesian patients.","volume":"23","author":"Malueka","year":"2022","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"noi250057r39","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/jnnp-2021-326138","article-title":"Cyproterone acetate and risk of meningioma: a nationwide cohort study.","volume":"93","author":"Mikkelsen","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"noi250057r40","doi-asserted-by":"publisher","first-page":"e2789","DOI":"10.1210\/clinem\/dgae739","article-title":"Further data against the use of cyproterone acetate in gender-affirming hormone therapy regimens.","volume":"110","author":"Slack","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"noi250057r41","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1200\/JCO.2007.14.2133","article-title":"Is there an association between meningioma and hormone replacement therapy?","volume":"26","author":"Blitshteyn","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"noi250057r42","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1093\/aje\/kwj254","article-title":"Risk of brain tumors associated with exposure to exogenous female sex hormones.","volume":"164","author":"Wigertz","year":"2006","journal-title":"Am J Epidemiol"},{"key":"noi250057r43","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3389\/fonc.2018.00651","article-title":"Relationships between neurofibromatosis-2, progesterone receptor expression, the use of exogenous progesterone, and risk of orbitocranial meningioma in females.","volume":"8","author":"Supartoto","year":"2019","journal-title":"Front Oncol"},{"issue":"4","key":"noi250057r44","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1055\/s-0041-1735553","article-title":"Regression of multiple meningiomas after discontinuation of chronic hormone therapy: a case report.","volume":"82","author":"Shahin","year":"2021","journal-title":"J Neurol Surg Rep"},{"issue":"5","key":"noi250057r45","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.neuchi.2015.05.002","article-title":"[Intra cranial meningiomas and long term use of cyproterone acetate with a conventional dose in women. a report of two cases of tumor decrease after treatment withdrawal].","volume":"61","author":"Botella","year":"2015","journal-title":"Neurochirurgie"},{"key":"noi250057r46","first-page":"Doc05","article-title":"Unilateral proptosis and blindness caused by meningioma in a patient treated with cyproterone acetate.","volume":"5","author":"Sys","year":"2015","journal-title":"GMS Ophthalmol Cases"},{"issue":"4","key":"noi250057r48","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00404-023-07265-5","article-title":"Depot medroxyprogesterone acetate and breast cancer: a systematic review.","volume":"309","author":"Z\u00fcrcher","year":"2024","journal-title":"Arch Gynecol Obstet"},{"key":"noi250057r49","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1097\/01.AOG.0000450758.95422.c8","article-title":"Depot medroxyprogesterone acetate and bone effects: committee opinion No. 602.","volume":"123","author":"American College of Obstetricians and Gynecologists","year":"2014","journal-title":"Obstet Gynecol"},{"key":"noi250057r50","article-title":"Use of contraception in the United States: 1982\u20132008.","author":"Mosher","year":"2010","journal-title":"Vital Health Stat"},{"issue":"8","key":"noi250057r51","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/pds.5482","article-title":"Core concepts in pharmacoepidemiology: fundamentals of the cohort and case-control study designs.","volume":"31","author":"Potteg\u00e5rd","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"noi250057r52","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jada.2010.03.029","article-title":"Lifestyle in France and the United States: an American perspective.","volume":"110","author":"Powell","year":"2010","journal-title":"J Am Diet Assoc"},{"issue":"2","key":"noi250057r54","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1093\/jnci\/djae253","article-title":"Grade-stratified meningioma risk among individuals who are non-Hispanic Black and interactions with male sex.","volume":"117","author":"Walsh","year":"2025","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"noi250057r55","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.3171\/2023.11.JNS23732","article-title":"Obesity and meningioma: a US population-based study paired with analysis of a multi-institutional cohort.","volume":"140","author":"Khazanchi","year":"2024","journal-title":"J Neurosurg"},{"issue":"5","key":"noi250057r56","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2217\/WHE.13.41","article-title":"Obesity and hormonal contraceptive efficacy.","volume":"9","author":"Robinson","year":"2013","journal-title":"Womens Health (Lond)"},{"issue":"1","key":"noi250057r57","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.contraception.2016.09.003","article-title":"Does body mass index or weight perception affect contraceptive use?","volume":"95","author":"Bhuva","year":"2017","journal-title":"Contraception"},{"issue":"1","key":"noi250057r58","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.contraception.2015.03.017","article-title":"Racial and ethnic differences in contraceptive use among women who desire no future children, 2006-2010 National Survey of Family Growth.","volume":"92","author":"Grady","year":"2015","journal-title":"Contraception"},{"issue":"1","key":"noi250057r59","doi-asserted-by":"publisher","first-page":"i13","DOI":"10.1093\/noajnl\/vdac107","article-title":"Meningioma in the elderly.","volume":"5","author":"Amoo","year":"2023","journal-title":"Neurooncol Adv"},{"issue":"1","key":"noi250057r60","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/sj.bjc.6604438","article-title":"Is the incidence of meningiomas underestimated? A regional survey.","volume":"99","author":"Larjavaara","year":"2008","journal-title":"Br J Cancer"},{"issue":"S01","key":"noi250057r61","first-page":"S1","article-title":"Skull base meningiomas as part of a novel meningioma syndrome associated with chronic depot medroxyprogesterone acetate use.","volume":"84","author":"Abou-Al-Shaar","year":"2023","journal-title":"J Neurol Surg B Skull Base"},{"issue":"1","key":"noi250057r62","doi-asserted-by":"publisher","first-page":"E121","DOI":"10.1152\/ajpendo.00418.2023","article-title":"The hormonal profile in women using combined monophasic oral contraceptive pills varies across the pill cycle: a temporal analysis of serum endogenous and exogenous hormones using liquid chromatography with tandem mass spectroscopy.","volume":"327","author":"Rodriguez","year":"2024","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"noi250057r64","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1016\/j.wneu.2020.11.175","article-title":"Relationship between oral contraceptives and the risk of gliomas and meningiomas: a dose-response meta-analysis and systematic review.","volume":"147","author":"Yang","year":"2021","journal-title":"World Neurosurg"},{"issue":"5","key":"noi250057r65","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3171\/jns.2002.97.5.1078","article-title":"Radiation-induced meningioma: a descriptive study of 253 cases.","volume":"97","author":"Sadetzki","year":"2002","journal-title":"J Neurosurg"},{"issue":"9","key":"noi250057r66","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/jamaneurol.2017.1406","article-title":"Association of genetic predisposition with solitary schwannoma or meningioma in children and young adults.","volume":"74","author":"Pathmanaban","year":"2017","journal-title":"JAMA Neurol"},{"key":"noi250057r47","doi-asserted-by":"crossref","unstructured":"United Nations Department of Economic and Social Affairs, Contraceptive Use by Method 2019: Data Booklet. Accessed August 4, 2025. doi:10.18356\/1bd58a10-en","DOI":"10.18356\/1bd58a10-en"},{"key":"noi250057r53","unstructured":"Mataillet? D. Is it better to be Black in France or America? Accessed August 4, 2025. https:\/\/france-amerique.com\/is-it-better-to-be-black-in-france-or-america\/"},{"key":"noi250057r63","unstructured":"Reed? BG, Carr? BR. The normal menstrual cycle and the control of ovulation. Accessed August 4, 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279054\/"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2838202\/jamaneurology_xiao_2025_oi_250057_1762755378.99598.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T16:00:36Z","timestamp":1762790436000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2838202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":66,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2025.3011","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}